Innoviva, Inc. (INVA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
INVA currently has 74.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 17.81% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 74.2M shares outstanding |
74M | 0 |
| Nov 05, 2025 |
10-Q filing | 69.1M shares outstanding |
69M | 0 |
| Aug 06, 2025 |
10-Q filing | 62.9M shares outstanding |
63M | 0 |
| May 07, 2025 |
10-Q filing | 62.7M shares outstanding |
63M | 0 |
| Feb 26, 2025 |
10-K filing | 62.7M shares outstanding |
63M | 0 |
| Nov 06, 2024 |
10-Q filing | 62.6M shares outstanding |
63M | 0 |
| Jul 31, 2024 |
10-Q filing | 62.5M shares outstanding |
63M | 0 |
| May 08, 2024 |
10-Q filing | 63.2M shares outstanding |
63M | 0 |
| Feb 29, 2024 |
10-K filing | 65.4M shares outstanding |
65M | 0 |
| Nov 01, 2023 |
10-Q filing | 65.0M shares outstanding |
65M | 0 |
| Aug 02, 2023 |
10-Q filing | 65.3M shares outstanding |
65M | 0 |
| May 09, 2023 |
10-Q filing | 67.8M shares outstanding |
68M | 0 |
| Feb 28, 2023 |
10-K filing | 69.6M shares outstanding |
70M | 0 |
| Nov 09, 2022 |
10-Q filing | 69.7M shares outstanding |
70M | 0 |
| Jul 27, 2022 |
10-Q filing | 69.6M shares outstanding |
70M | 0 |
| Jul 20, 2022 |
8-K filing: Innoviva, Inc. closed the sale of 750 Class A Units and 750 Class C Units of Theravance Respiratory Company, LLC to Royalty Pharma Investments 2019 ICAV on July 20, 2022. |
70M | 0 |
| Jul 13, 2022 |
8-K filing: Innoviva, Inc. entered into a definitive equity purchase agreement with Royalty Pharma Investments 2019 ICAV, to sell 750 Class A Units and 750 Class C Units of Theravance Respiratory Company, LLC for approximately $281.9 million upfront and a potential $50 million milestone payment. ($281.9M proceeds) |
70M | 0 |
| May 05, 2022 |
10-Q filing | 69.5M shares outstanding |
70M | 0 |
| Feb 28, 2022 |
10-K filing | 69.6M shares outstanding |
70M | 0 |
| Oct 27, 2021 |
10-Q filing | 69.5M shares outstanding |
69M | 0 |
| Jul 29, 2021 |
10-Q filing | 69.5M shares outstanding |
69M | 0 |
| May 20, 2021 |
8-K filing: Innoviva, Inc. entered into a share repurchase agreement to purchase 32,005,260 shares of its common stock from Glaxo Group Limited for $12.25 per share, totaling $392,064,435. ($392.06M proceeds) |
100M | 0 |
| Apr 28, 2021 |
10-Q filing | 101.4M shares outstanding |
100M | 0 |
| Feb 25, 2021 |
10-K filing | 101.3M shares outstanding |
100M | 0 |
| Oct 28, 2020 |
10-Q filing | 101.4M shares outstanding |
100M | 0 |
| Jul 29, 2020 |
10-Q filing | 101.3M shares outstanding |
100M | 0 |
| Apr 29, 2020 |
10-Q filing | 101.2M shares outstanding |
100M | 0 |
| Feb 19, 2020 |
10-K filing | 101.2M shares outstanding |
100M | 0 |